Yilan Fu

The application of group cognitive behavioral intervention to T2DM treatment

Wei Jin, Qiu-hua Wu, Zhi-lei He, 2021 .

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors.

Dehua Liao, Ting Yan, Lun Yu, 2022, International immunopharmacology.

Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor–Mutated Non-Small Cell Lung Cancer Patients

N. Yang, Yongchang Zhang, Lizhi Cao, 2020, Frontiers in Pharmacology.

Salvianolic Acid B Improves Chronic Mild Stress-Induced Depressive Behaviors in Rats: Involvement of AMPK/SIRT1 Signaling Pathway

Lizhi Cao, Yujin Guo, Changshui Wang, 2020, Journal of inflammation research.

Subspace Clustering Based on Latent Low Rank Representation with Schatten-p Norm

B. Ling, Jiangzhong Cao, Yilan Fu, 2020, 2020 2nd World Symposium on Artificial Intelligence (WSAI).

Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events

Lun Yu, Jin-Sen Tang, Yilan Fu, 2024, Frontiers in immunology.

Positive effect of cognitive-behavioral intervention combined with integrated health care on patients with type 2 diabetes.

Wei Jin, Qiu-hua Wu, Yilan Fu, 2022, American journal of translational research.

Kaempferol Improves Breast Cancer-Related Depression through the COX-2/PGE2 Pathway.

Qing Zhu, Yuanshan Han, Yilan Fu, 2023, Frontiers in bioscience.